NK Plus T

NK Plus T appears to refer to an **experimental immunotherapy platform** that combines engineered natural killer cells with engineered T cells, rather than to a single well-defined pharmaceutical product. Publicly available references describe it in the context of preclinical work combining CAR-NK and CAR-T cells to achieve rapid cytotoxic activity from NK cells together with more durable antitumor persistence from T cells. Because the term is used as a platform label and not as a clearly standardized drug name with a fixed composition, sponsor, manufacturing definition, formulation, or clinical product specification, it should be treated as a non-specific investigational cell therapy concept rather than a uniquely identifiable marketed or clinical-stage drug.

Other names

NK Plus TNK plus T platform